MDXG

+ Watchlist + Portfolio

MiMedx Group, Inc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.45
52-Week Range: $3.03 – $7.97
Market Cap: $626.77M
P/E (TTM): 107.50
EPS (TTM): 0.04
Dividend Yield: —

Advanced Metrics

Price/Book: 2.90
PEG Ratio: 2.88
Return on Equity: 2.88%
Return on Assets: 1.91%
Gross Margin: 78.85%
Operating Margin: -28.69%
Profit Margin: 1.76%
Current Ratio: 5.33
Debt/Equity: 0.08
Total Debt: $17.21M
Free Cash Flow: $41.43M
Revenue Growth: -34.70%
Earnings Growth: —
Enterprise Value: $508.14M

MDXG Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$267.84M	$321.48M	$348.88M	$418.63M
Cost of Revenue	$48.32M	$54.63M	$60.07M	$73.01M
Gross Profit	$219.53M	$266.84M	$288.81M	$345.62M
Research & Development	$12.70M	$12.66M	$12.34M	$15.10M
Selling, General & Admin	$208.67M	$211.12M	$225.09M	$266.19M
Operating Expenses	$234.25M	$229.73M	$229.50M	$281.73M
Operating Income	-$14.73M	$37.12M	$59.31M	$63.89M
EBITDA	-$10.69M	$40.54M	$65.35M	$78.77M
Pretax Income	-$19.75M	$30.63M	$57.29M	$66.26M
Income Tax	$206.00K	-$36.81M	$15.30M	$17.68M
Net Income	-$30.20M	$58.23M	$42.42M	$48.58M
Diluted EPS	-0.33	0.37	0.28	0.32
Diluted Shares	112.91M	145.96M	149.05M	149.72M

MDXG Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$65.95M	$82.00M	$104.42M	$166.12M
Receivables	$43.08M	$53.87M	$55.83M	$75.71M
Inventory	$13.18M	$21.02M	$23.81M	$25.34M
Current Assets	$134.20M	$164.26M	$191.89M	$277.47M
Total Assets	$171.43M	$239.05M	$263.92M	$342.65M
Current Liabilities	$43.56M	$46.01M	$45.59M	$64.27M
Long-Term Debt	$48.59M	$48.10M	$17.83M	$16.47M
Total Debt	$48.59M	$49.10M	$18.83M	$17.97M
Total Liabilities	$189.42M	$96.33M	$70.81M	$86.11M
Retained Earnings	-$191.91M	-$133.68M	-$91.26M	-$42.68M
Shareholders' Equity	-$17.99M	$142.72M	$193.11M	$256.55M
Working Capital	$90.64M	$118.25M	$146.29M	$213.21M

MDXG Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.89M	$26.77M	$66.20M	$74.00M
Capital Expenditure	-$1.51M	-$1.99M	-$1.68M	-$1.03M
Free Cash Flow	-$19.41M	$24.79M	$64.52M	$72.97M
Depreciation & Amortisation	$4.05M	$3.43M	$6.04M	$14.88M
Stock-Based Compensation	$11.33M	$16.96M	$16.93M	$16.40M
Investing Cash Flow	-$2.66M	-$2.15M	-$9.58M	-$6.89M
Financing Cash Flow	-$580.00K	-$8.57M	-$34.20M	-$5.41M
Share Repurchases	-$1.19M	-$9.52M	-$2.64M	-$3.12M
Net Change in Cash	-$21.13M	$16.05M	$22.42M	$61.70M

MDXG Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$98.61M	$113.72M	$118.09M	$58.99M	$64.36M
Cost of Revenue	$18.68M	$18.72M	$19.05M	$17.37M	$19.98M
Gross Profit	$79.92M	$95.01M	$99.04M	$41.62M	$44.38M
Research & Development	$3.30M	$3.70M	$4.76M	$4.14M	$2.78M
Selling, General & Admin	$64.15M	$69.00M	$73.07M	$53.23M	$59.78M
Operating Expenses	$67.55M	$72.82M	$77.96M	$57.67M	$62.85M
Operating Income	$12.37M	$22.19M	$21.08M	-$16.05M	-$18.47M
EBITDA	$15.54M	$27.48M	$24.30M	-$13.31M	-$16.93M
Pretax Income	$13.01M	$22.85M	$21.80M	-$15.33M	-$17.78M
Income Tax	$3.39M	$6.10M	$6.60M	-$4.47M	-$2.94M
Net Income	$9.62M	$16.75M	$15.19M	-$10.86M	-$14.84M
Diluted EPS	0.06	0.11	0.10	-0.07	-0.10
Diluted Shares	149.32M	149.71M	150.19M	148.45M	147.80M

MDXG Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$118.87M	$142.08M	$166.12M	$159.77M	$135.84M
Receivables	$69.23M	$78.19M	$75.71M	$46.03M	$41.30M
Inventory	$24.89M	$26.50M	$25.34M	$26.23M	$20.93M
Current Assets	$220.88M	$254.09M	$277.47M	$240.33M	$205.37M
Total Assets	$291.11M	$318.99M	$342.65M	$308.68M	$281.00M
Current Liabilities	$50.29M	$57.68M	$64.27M	$44.55M	$38.50M
Long-Term Debt	$17.21M	$16.84M	$16.47M	$16.09M	$15.71M
Total Debt	$18.46M	$18.21M	$17.97M	$17.59M	$17.21M
Total Liabilities	$74.48M	$80.04M	$86.11M	$65.74M	$65.00M
Retained Earnings	-$74.62M	-$57.87M	-$42.68M	-$53.54M	-$68.38M
Shareholders' Equity	$216.62M	$238.95M	$256.55M	$242.94M	$216.00M
Working Capital	$170.59M	$196.41M	$213.21M	$195.78M	$166.87M

MDXG Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$14.42M	$29.33M	$24.96M	$1.88M	-$10.02M
Capital Expenditure	-$216.00K	-$3.92M	—	-$570.00K	-$707.00K
Free Cash Flow	$14.20M	$25.41M	$28.43M	$1.31M	-$10.72M
Depreciation & Amortisation	$3.17M	$5.29M	$3.22M	$1.62M	$1.53M
Stock-Based Compensation	$4.75M	$4.92M	$2.46M	-$1.70M	$903.00K
Investing Cash Flow	-$887.00K	-$5.26M	-$335.00K	-$5.64M	-$635.00K
Financing Cash Flow	-$1.09M	-$857.00K	-$583.00K	-$2.58M	-$13.28M
Share Repurchases	-$526.00K	-$83.00K	-$51.00K	-$1.90M	-$12.60M
Net Change in Cash	$12.44M	$23.21M	$24.04M	-$6.35M	-$23.93M

Market Snapshot

About

MiMedx Group, Inc. is a biopharmaceutical company focused on developing and distributing regenerative and therapeutic biologics utilizing human placental tissue allografts. The company provides advanced wound care and surgical products derived from amniotic tissue for applications in wound care, orthopedics, spine, and sports medicine.